Dan Lü

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

Anna Yemelyanova, Russell Vang, Malti Kshirsagar et al. · Modern Pathology · 2011 · 523 citations · Full text

Oncology, Tumor Heterogeneity, Medicine +9

Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin

Chester Lee Drum, Shui-Zhong Yan, Joel Bard et al. · Nature · 2002 · 420 citations

Biochemistry, Natural Sciences, Mechanism Of Action +4

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles et al. · The Lancet Oncology · 2015 · 326 citations

Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia, Medicine +9

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani et al. · The Lancet Haematology · 2019 · 243 citations · Full text

Lymphoid Neoplasia, Pinatuzumab Vedotin, Medicine +9

Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity

Dan Lü, Juqun Shen, Marie Danielle Vil et al. · Journal of Biological Chemistry · 2003 · 183 citations · Full text